Heart Failure With Mildly Reduced Ejection Fraction
7
5
5
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
43%
3 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (7)
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Pharmacological Optimization in Prevention in Heart Failure: A Sex-gap?
PBMC as Biomarkers of Diabetic Cardiomyopathy
Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
Iron Deficiency in Patients With Heart Failure and Reduced and Mildly Reduced Ejection Fraction
CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction